NYSEAMERICAN:AST Asterias Biotherapeutics (AST) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free AST Stock Alerts $0.0020 -0.94 (-99.79%) (As of 07/10/2019) Add Compare Share Share Today's Range$0.0020▼$0.002050-Day Range N/A52-Week Range$0.51▼$2.05Volume1,000 shsAverage Volume136,653 shsMarket Capitalization$111,318.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Asterias Biotherapeutics alerts: Email Address Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Asterias Biotherapeutics Stock (NYSEAMERICAN:AST)Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.Read More AST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AST Stock News HeadlinesMarch 27, 2024 | seekingalpha.comCLDI Calidi Biotherapeutics, Inc.February 17, 2024 | morningstar.comProtalix BioTherapeutics Inc PLXApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.November 27, 2023 | benzinga.comCalidi Biotherapeutics Stock (AMEX:CLDI) Dividends: History, Yield and DatesNovember 22, 2023 | morningstar.comBarinthus Biotherapeutics PLC ADRNovember 2, 2023 | morningstar.comCalidi Biotherapeutics Inc Ordinary Shares - Class AJuly 18, 2023 | benzinga.comArcutis Biotherapeutics Stock (NASDAQ:ARQT), Analyst Ratings, Price Targets, PredictionsMay 21, 2023 | fool.comIovance Biotherapeutics (NASDAQ: IOVA)April 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.May 11, 2023 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market Future Investments and Forecast Till 2030May 8, 2023 | investing.comBrightPath Biotherapeutics Co Ltd (4594)March 14, 2023 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market: Analyzing Growth Opportunities and Industry Trends for 2023-2028March 9, 2023 | marketwatch.com2023-2029 Human Embryonic Stem Cells (HESC) Market Size and Regional Analysis | Research Report by Absolute ReportsMarch 7, 2023 | marketwatch.comStem Cell Therapy for Osteoarthritis Market Expert Industrial Investigation Report 2023-2028March 6, 2023 | marketwatch.comTherapeutic Cancer Vaccines Market 2023 | Global Industry Report Forecast 2029February 27, 2023 | marketwatch.comEmerging Opportunities in Therapeutic Cancer Vaccines Market from 2023 to 2027February 20, 2023 | seekingalpha.comAtara Biotherapeutics, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 14, 2023 | marketwatch.comTherapeutic Cancer Vaccines Market Outlook 2023 and Forecast to 2028 with Top Countries DataJanuary 30, 2023 | finance.yahoo.comBridge Biotherapeutics to Present at BIOTECH SHOWCASE™ 2023January 20, 2023 | seekingalpha.comSONN Sonnet BioTherapeutics Holdings, Inc.January 19, 2023 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market By Industry Research, Supply, Size, Share and Prospects 2023-2028January 11, 2023 | marketwatch.comSonnet BioTherapeutics Shares Up 8% on Roche CollaborationJanuary 5, 2023 | finance.yahoo.comKling Biotherapeutics Appoints Michael Koslowski, M.D. As Chief Executive OfficerDecember 20, 2022 | finance.yahoo.comSensei Biotherapeutics Slashes Workforce, Closes R&D SiteNovember 27, 2022 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market 2022 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028November 27, 2022 | marketwatch.comHuman Embryonic Stem Cells (HESC) Market 2022 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028November 25, 2022 | marketwatch.comTherapeutic Cancer Vaccines Market 2023 : SWOT Analysis by Players Continues Explosive Growth by 2028See More Headlines Receive AST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Asterias Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2017Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:AST Previous SymbolNYSEMKT:AST CUSIPN/A CIKN/A Webasteriasbiotherapeutics.com Phone+1-510-4563805FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares55,659,000Free FloatN/AMarket Cap$111,318.00 OptionableNot Optionable BetaN/A The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Michael H. Mulroy (Age 53)CEO, Pres & Director Dr. Edward D. Wirth III (Age 54)Chief Medical Officer Dr. Katharine E. Spink (Age 45)Consultant Mr. Stephen L. Cartt (Age 56)Advisor & Director Mr. Ryan D. Chavez (Age 43)CFO & Gen. Counsel Key CompetitorsPolarityTENASDAQ:PTEIQRespireRx PharmaceuticalsOTCMKTS:RSPIDDiadexusOTCMKTS:DDXSNovaBay PharmaceuticalsNYSEAMERICAN:NBYScopus BioPharmaNASDAQ:SCPSView All Competitors AST Stock Analysis - Frequently Asked Questions How were Asterias Biotherapeutics' earnings last quarter? Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) announced its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to the consensus estimate of $2.81 million. What other stocks do shareholders of Asterias Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), Amarin (AMRN), Anavex Life Sciences (AVXL) and Freeport-McMoRan (FCX). How do I buy shares of Asterias Biotherapeutics? Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:AST) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Asterias Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
